propoxyphene (Darvon, Dolene, Proxagesic, Novopropoxyn)

From Aaushi
Jump to navigation Jump to search

Introduction

(propoxyphene hydrochloride) Tradenames: Darvon, Dolene. DEA-controlled substance: class 4. Banned by FDA Feb 2009.[5] Withdrawn from US market Nov 2010.[9]

Indications

  • relief of mild to moderate pain*

* Not appropriate for severe pain Never shown to be superior to aspirin or acetaminophen

Dosage

65 mg PO every 4 hours

Tabs: 32 & 65 mg.

100 mg of propoxyphene is equal in analgesia to 60 mg of codeine or 650 mg of aspirin

Pharmacokinetics

1/2life = 8-24 hours

1/2life = 18-29 hours norpropoxyphene

protein binding = 76 %

elimination by hemodialysis = -

elimination by peritoneal dialysis = -

Adverse effects

Drug interactions

  • smoking may increase hepatic metabolism

Laboratory

Mechanism of action

More general terms

Component of

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. The Pharmacological Basis of Therapeutics, 8th ed. Gilman et al, eds. Permagon Press/McGraw Hill
  3. Clinical Guide to Laboratory Tests, NW Tietz (ed) 3rd ed, WB Saunders, Philadelpha 1995
  4. 4.0 4.1 Geriatrics Review Syllabus, American Geriatrics Society, 5th edition, 2002-2004
  5. 5.0 5.1 FDA panel recommends ban on the painkiller Darvon http://www.google.com/hostednews/ap/article/ALeqM5iimSGh-TXwePdZHMMlPq4MBSdKGgD961N61O0
    FDA holds safety hearing on 50-year-old painkiller http://www.google.com/hostednews/ap/article/ALeqM5iimSGh-TXwePdZHMMlPq4MBSdKGgD961J3U00
  6. Darvon Label http://www.xanodyne.com/pdf/Darvon.pdf
  7. Prescriber's Letter 16(3): 2009 Propoxyphene: Safety and Efficacy Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=250301&pb=PRL (subscription needed) http://www.prescribersletter.com
  8. Propoxyphene-containing Products FDA MedWatch http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm170763.htm
  9. 9.0 9.1 9.2 FDA MmedWatch, 11/19/2010 Propoxyphene: Withdrawal - Risk of Cardiac Toxicity http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm234389.htm
  10. Prescriber's Letter 17(12): 2010 COMMENTARY: Propoxyphene Withdrawal from the Market Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=261228&pb=PRL (subscription needed) http://www.prescribersletter.com

Patient information

propoxyphene patient information

Database